Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions
Philogen announces its attendance at the Antibody Engineering & Therapeutics 2022. Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small...
Philogen is Sponsor at the 13th edition of Melanoma Bridge in Naples, 1-3 December 2022. For further details
Philogen announces publication in Protein Science on the selection and structural characterization of a novel PD-1 blocking antibody
The study describes the development of a novel anti-PD-1 antibody that shows potent blockade of PD-1 with a different recognition mechanism compared to anti-PD-1...
Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details